GLP-1 Drugs (Canada): 2024 Pulse Survey
A new survey report reveals results from a group of Canadian employers regarding considerations and coverage for glucagon-like peptide-1 (GLP-1) drugs, which have historically been used to treat diabetes and are increasingly being used to treat obesity. It also provides a snapshot of other approaches used by employers that offer health care coverage to address certain chronic health conditions. The data reflects responses from 82 Canadian corporate plan sponsors, professional service providers and multi-employer plans.
Coverage of GLP-1 Drugs (n=82)
Considering Offering Coverage for GLP-1 Drugs for Weight Loss* (n=54)
*Respondents who only offer GLP-1 drugs for diabetes answered this question.
Extended Group Health Plan Funding (n=79)
Top Ten Factors When Considering GLP-1 Coverage for Obesity Care* (n=15**)
*Respondents were asked to select all that apply.
**Due to small number of responses, please use caution when generalizing findings to a particular population.
There's more! View a full listing of International Foundation benchmarking and pulse survey reports.
Survey reports are just one of the many helpful products and services included with an International Foundation membership.